Official signing ceremony for WIBP strategic alliance

    MONTREAL, June 5 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX:PLI)
("ProMetic") announced today that the official signing ceremony for the
strategic alliance concluded earlier this year with the Wuhan Institute of
Biological Products ("WIBP") a subsidiary of China National Biotec Group
("CNBG") was held on Wednesday, June 4, 2008 at CNBG's Beijing location.
    Present at the signing were CNBG's President and Chief Executive Officer
Ms. Lifeng Wang, WIBP's Director Dr. Xiaoming Yang, ProMetic's President and
Chief Executive Officer Mr. Pierre Laurin as well as several officials from
the CNBG and WIBP organizations. Additional information is available on CNBG's
web site at and on WIBP's web site at

    More about Wuhan Institute of Biological Products

    WIBP ( or, located in Wuhan, China. is
one of the subsidiaries of CNBG, has over 50 years experience in the fields of
biomedical research and product development; historically strong in R&D, WIBP
is the only institute certified by state to offer doctoral program among six
Institute of Biological Products in CNBG. Today, WIBP has more than
1,000 employees, and major products include two dozen vaccines and plasma
derivatives currently marketed throughout the China.

    More about China National Biotec Group

    CNBG ( or, headquartered in Beijing,
China, is a state-owned enterprise and the largest biotech company in China
dedicated to discover, develop, manufacture and market a broad range of human
health products, including vaccines, blood derivatives, biopharmaceuticals,
diagnostic reagents and others. With more than 9,000 employees and revenues of
421 million USD in 2006, CNBG is the largest producer of vaccines and blood
derivatives in China, enjoying more than 80% and 30% market share
respectively. The company consists of 6 Institute of Biological Products and
an international trading company.

    About ProMetic Life Sciences Inc.

    ProMetic ( is a biopharmaceutical company specialized in
the research, development, manufacture and marketing of a variety of
commercial applications derived from its proprietary Mimetic Ligand(TM)
technology. This technology is used in large-scale purification of biologics
and the elimination of pathogens. ProMetic is also active in therapeutic drug
development with the mission to bring to market effective, innovative, lower
cost, less toxic products for the treatment of hematology and cancer. Its drug
discovery platform is focused on replacing complex, expensive proteins with
synthetic "drug-like" protein mimetics. Headquartered in Montréal (Canada),
ProMetic has R&D facilities in the U.K., the U.S. and Canada, manufacturing
facilities in the U.K. and business development activities in the U.S.,
Europe, Asia and in the Middle-East.

For further information:

For further information: Company Inquiries: Pierre Laurin, President and
CEO, ProMetic Life Sciences Inc., (514) 341-2115,;
Dominic Sicotte, Echoes Financial Network Inc., (514) 842-9551,; Anne Leduc, Manager, Investor Relations &
Communications, ProMetic Life Sciences Inc., (514) 341-2115,; Investor Relations: Bruce Voss, Lippert / Heilshorn &
Associates, (310) 691-7100,; Kim Golodetz, Lippert / Heilshorn
& Associates, (212) 838-3777,; Media Relations: Jules
Abraham, Lippert / Heilshorn & Associates, (212) 838-3777,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890